Alk-Abello A-S News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

25.01.23	U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents (PR Newswire)
01.12.21	The Lancet Regional Health - Europe publishes 'real-world evidence' from ALK-sponsored study confirming long-term benefits of allergy immunotherapy in allergic rhinitis and asthma (PR Newswire)
12.03.19	The pollen season kicks off with an award-winning pollen app (GlobeNewswire)
26.02.19	New data shows ALK’s house dust mite SLIT-tablet significantly improves quality of sleep for allergic rhinitis patients (GlobeNewswire)
17.10.18	UK authority extends use of specific batches of Jext® as adrenaline pen shortage continues (GlobeNewswire)
27.05.18	Allergy experts: "Clinical effect of ALK’s tree SLIT-tablet among the most significant ever seen in allergy immunotherapy trials" (GlobeNewswire)
04.05.18	Three-month interim report (Q1) 2018 (GlobeNewswire)
01.05.18	Release date of three-month interim report (Q1) 2018 and audio cast (GlobeNewswire)
18.04.18	ALK’s partner for Japan, Torii, secures pricing for new Japanese cedar SLIT-tablet (GlobeNewswire)
11.04.18	ALK announces allergy diagnostic partnership with Rellergen in China (GlobeNewswire)
20.03.18	Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff (GlobeNewswire)
20.03.18	Grant of share options and performance shares to members of the Board of Management and key employees (GlobeNewswire)
16.03.18	Articles of Association (GlobeNewswire)
07.07.17	ALK - Five-year GRAZAX® Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children (PR Newswire)
30.06.17	ALK: Five-year GRAZAX® Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children (PR Newswire)
30.06.17	ALK: Five-year GRAZAX® Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children (PR Newswire)
20.06.17	ALK Symposium Reveals Early Treatment is Critical for Respiratory Allergic Disease in Children and Adolescents (PR Newswire)
03.03.17	ALK Appoints SVP of R&D for North America and International Markets (PR Newswire)
03.03.17	ALK Appoints SVP of R&D for North America and International Markets (PR Newswire)
02.03.17	ALK Announces FDA Approval for its House Dust Mite Sublingual Allergy Immunotherapy Tablet (ACARIZAX® in Europe) (PR Newswire)
02.03.17	ALK Announces FDA Approval for its House Dust Mite Sublingual Allergy Immunotherapy Tablet (ACARIZAX® in Europe) (PR Newswire)
27.02.17	ALK’s ACARIZAX® Data Results in Significant Change to the GINA Asthma Management Strategy: Sublingual Allergy Immunotherapy (SLIT) Recommended as a Treatment Option in Patients With House Dust Mite... (PR Newswire)
27.02.17	ALK’s ACARIZAX® Data Results in Significant Change to the GINA Asthma Management Strategy: Sublingual Allergy Immunotherapy (SLIT) Recommended as a Treatment Option in Patients With House Dust Mite... (PR Newswire)
10.06.15	ALK’s partner, MSD, publishes Phase II data on house dust mite SLIT-tablet in leading allergy journal (Businesswire)
08.06.15	ALK: EAACI Annual Congress in Barcelona: Analysis of the International Guidelines for House Dust Mite Respiratory Allergy and the Need to Take an Integrated Approach. (Businesswire)
02.03.12	DGAP-News: Alk-Abello A/S (B) (EQS Group)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Alk-Abello A-S (B)

Aktien Top/Flop

Meistgelesene Nachrichten